Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Here, we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) therapy in second-line relapsed/refractory large B-cell lymphoma (R/R LBCL) from the pivotal randomized phase 3 ZUMA-7 study of axicabtagene cilo...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
24 November 2022
|
| In: |
Blood
Year: 2022, Jahrgang: 140, Heft: 21, Pages: 2248-2260 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood.2022015478 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2022015478
|
| Verfasserangaben: | Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Paul Cheng, Christina To, and Marie José Kersten |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1843591235 | ||
| 003 | DE-627 | ||
| 005 | 20240327080246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230426s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2022015478 |2 doi | |
| 035 | |a (DE-627)1843591235 | ||
| 035 | |a (DE-599)KXP1843591235 | ||
| 035 | |a (OCoLC)1389533901 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Elsawy, Mahmoud |e VerfasserIn |0 (DE-588)128704865X |0 (DE-627)1843592886 |4 aut | |
| 245 | 1 | 0 | |a Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma |c Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Paul Cheng, Christina To, and Marie José Kersten |
| 264 | 1 | |c 24 November 2022 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar 19 July 2022, Version des Artikels 24 November 2022 | ||
| 500 | |a Gesehen am 26.04.2023 | ||
| 520 | |a Here, we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) therapy in second-line relapsed/refractory large B-cell lymphoma (R/R LBCL) from the pivotal randomized phase 3 ZUMA-7 study of axicabtagene ciloleucel (axi-cel) vs SOC. PRO instruments were administered at baseline, day 50, day 100, day 150, month 9, and every 3 months from randomization until 24 months or an event-free survival event. The quality of life (QoL) analysis set comprised patients with a baseline and ≥1 follow-up PRO completion. Prespecified hypotheses for Quality of Life Questionnaire-Core 30 (QLQ-C30) physical functioning, global health status/QoL, and EQ-5D-5L visual analog scale (VAS) were tested using mixed-effects models with repeated measures. Clinically meaningful changes were defined as 10 points for QLQ-C30 and 7 for EQ-5D-5L VAS. Among 359 patients, 296 (165 axi-cel, 131 SOC) met inclusion criteria for QoL analysis. At day 100, statistically significant and clinically meaningful differences in mean change of scores from baseline were observed favoring axi-cel over SOC for QLQ-C30 global health status/QoL (estimated difference 18.1 [95% confidence interval (CI), 12.3-23.9]), physical functioning (13.1 [95% CI, 8.0-18.2]), and EQ-5D-5L VAS (13.7 [95% CI, 8.5-18.8]; P < .0001 for all). At day 150, scores significantly favored axi-cel vs SOC for global health status/QoL (9.8 [95% CI, 2.6-17.0]; P = .0124) and EQ-5D-5L VAS (11.3 [95% CI, 5.4-17.1]; P = .0004). Axi-cel showed clinically meaningful improvements in QoL over SOC. Superior clinical outcomes and favorable patient experience with axi-cel should help inform treatment choices in second-line R/R LBCL. This trial was registered at www.clinicaltrials.gov as #NCT03391466. | ||
| 700 | 1 | |a Chavez, Julio C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Avivi, Irit |e VerfasserIn |4 aut | |
| 700 | 1 | |a Larouche, Jean-François |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wannesson, Luciano |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cwynarski, Kate |e VerfasserIn |4 aut | |
| 700 | 1 | |a Osman, Keren |e VerfasserIn |4 aut | |
| 700 | 1 | |a Davison, Kelly |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rudzki, Jakob D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dahiya, Saurabh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dorritie, Kathleen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jaglowski, Samantha |e VerfasserIn |4 aut | |
| 700 | 1 | |a Radford, John |e VerfasserIn |4 aut | |
| 700 | 1 | |a Morschhauser, Franck |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cunningham, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Martin Garcia-Sancho, Alejandro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tzachanis, Dimitrios |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ulrickson, Matthew L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Karmali, Reem |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kekre, Natasha |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thieblemont, Catherine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Enblad, Gunilla |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Malladi, Ram |e VerfasserIn |4 aut | |
| 700 | 1 | |a Joshi, Namita |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wang, Wei-Jhih |e VerfasserIn |4 aut | |
| 700 | 1 | |a Solem, Caitlyn T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Snider, Julia Thornton |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cheng, Paul |e VerfasserIn |4 aut | |
| 700 | 1 | |a To, Christina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kersten, Marie José |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d Washington, DC : American Society of Hematology, 1946 |g 140(2022), 21 vom: Nov., Seite 2248-2260 |h Online-Ressource |w (DE-627)266886647 |w (DE-600)1468538-3 |w (DE-576)075961938 |x 1528-0020 |7 nnas |a Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma |
| 773 | 1 | 8 | |g volume:140 |g year:2022 |g number:21 |g month:11 |g pages:2248-2260 |g extent:13 |a Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma |
| 856 | 4 | 0 | |u https://doi.org/10.1182/blood.2022015478 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230426 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 23 | ||
| 999 | |a KXP-PPN1843591235 |e 431451261X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"24 November 2022","dateIssuedKey":"2022"}],"recId":"1843591235","type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"origin":[{"dateIssuedKey":"1946","dateIssuedDisp":"1946-","publisher":"American Society of Hematology ; Saunders ; HighWire Press","publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif."}],"recId":"266886647","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"Blood online"}],"corporate":[{"role":"isb","display":"American Society of Hematology"}],"note":["Gesehen am 21.04.2023"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphomaBlood","id":{"zdb":["1468538-3"],"issn":["1528-0020"],"eki":["266886647"]},"part":{"volume":"140","text":"140(2022), 21 vom: Nov., Seite 2248-2260","year":"2022","issue":"21","extent":"13","pages":"2248-2260"},"language":["eng"],"title":[{"title":"Blood","subtitle":"journal of the American Society of Hematology","title_sort":"Blood"}],"pubHistory":["1.1946 -"]}],"note":["Online verfügbar 19 July 2022, Version des Artikels 24 November 2022","Gesehen am 26.04.2023"],"physDesc":[{"extent":"13 S."}],"id":{"doi":["10.1182/blood.2022015478"],"eki":["1843591235"]},"name":{"displayForm":["Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Paul Cheng, Christina To, and Marie José Kersten"]},"person":[{"role":"aut","given":"Mahmoud","display":"Elsawy, Mahmoud","family":"Elsawy"},{"family":"Chavez","given":"Julio C.","role":"aut","display":"Chavez, Julio C."},{"family":"Avivi","given":"Irit","role":"aut","display":"Avivi, Irit"},{"family":"Larouche","role":"aut","given":"Jean-François","display":"Larouche, Jean-François"},{"given":"Luciano","role":"aut","display":"Wannesson, Luciano","family":"Wannesson"},{"family":"Cwynarski","role":"aut","given":"Kate","display":"Cwynarski, Kate"},{"role":"aut","given":"Keren","display":"Osman, Keren","family":"Osman"},{"family":"Davison","role":"aut","given":"Kelly","display":"Davison, Kelly"},{"family":"Rudzki","display":"Rudzki, Jakob D.","given":"Jakob D.","role":"aut"},{"given":"Saurabh","role":"aut","display":"Dahiya, Saurabh","family":"Dahiya"},{"given":"Kathleen","role":"aut","display":"Dorritie, Kathleen","family":"Dorritie"},{"display":"Jaglowski, Samantha","given":"Samantha","role":"aut","family":"Jaglowski"},{"family":"Radford","display":"Radford, John","given":"John","role":"aut"},{"family":"Morschhauser","display":"Morschhauser, Franck","given":"Franck","role":"aut"},{"display":"Cunningham, David","given":"David","role":"aut","family":"Cunningham"},{"role":"aut","given":"Alejandro","display":"Martin Garcia-Sancho, Alejandro","family":"Martin Garcia-Sancho"},{"family":"Tzachanis","display":"Tzachanis, Dimitrios","role":"aut","given":"Dimitrios"},{"display":"Ulrickson, Matthew L.","role":"aut","given":"Matthew L.","family":"Ulrickson"},{"family":"Karmali","role":"aut","given":"Reem","display":"Karmali, Reem"},{"family":"Kekre","given":"Natasha","role":"aut","display":"Kekre, Natasha"},{"display":"Thieblemont, Catherine","given":"Catherine","role":"aut","family":"Thieblemont"},{"display":"Enblad, Gunilla","given":"Gunilla","role":"aut","family":"Enblad"},{"family":"Dreger","display":"Dreger, Peter","given":"Peter","role":"aut"},{"family":"Malladi","display":"Malladi, Ram","role":"aut","given":"Ram"},{"given":"Namita","role":"aut","display":"Joshi, Namita","family":"Joshi"},{"family":"Wang","given":"Wei-Jhih","role":"aut","display":"Wang, Wei-Jhih"},{"given":"Caitlyn T.","role":"aut","display":"Solem, Caitlyn T.","family":"Solem"},{"given":"Julia Thornton","role":"aut","display":"Snider, Julia Thornton","family":"Snider"},{"role":"aut","given":"Paul","display":"Cheng, Paul","family":"Cheng"},{"display":"To, Christina","role":"aut","given":"Christina","family":"To"},{"given":"Marie José","role":"aut","display":"Kersten, Marie José","family":"Kersten"}],"language":["eng"],"title":[{"title_sort":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma"}]} | ||
| SRT | |a ELSAWYMAHMPATIENTREP2420 | ||